1. Home
  2. ASG vs ANNX Comparison

ASG vs ANNX Comparison

Compare ASG & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASG

Liberty All-Star Growth Fund Inc.

HOLD

Current Price

$5.44

Market Cap

334.6M

Sector

Finance

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.08

Market Cap

334.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASG
ANNX
Founded
1986
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
334.6M
334.1M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
ASG
ANNX
Price
$5.44
$5.08
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$16.50
AVG Volume (30 Days)
324.3K
2.9M
Earning Date
01-01-0001
11-10-2025
Dividend Yield
8.09%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.47
$1.29
52 Week High
$5.71
$5.48

Technical Indicators

Market Signals
Indicator
ASG
ANNX
Relative Strength Index (RSI) 58.86 58.10
Support Level $5.26 $4.55
Resistance Level $5.42 $5.23
Average True Range (ATR) 0.06 0.32
MACD 0.01 -0.06
Stochastic Oscillator 98.51 55.61

Price Performance

Historical Comparison
ASG
ANNX

About ASG Liberty All-Star Growth Fund Inc.

Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: